CA2285960A1 - Use of lactoferin in the treatment of allergen induced disorders - Google Patents

Use of lactoferin in the treatment of allergen induced disorders Download PDF

Info

Publication number
CA2285960A1
CA2285960A1 CA002285960A CA2285960A CA2285960A1 CA 2285960 A1 CA2285960 A1 CA 2285960A1 CA 002285960 A CA002285960 A CA 002285960A CA 2285960 A CA2285960 A CA 2285960A CA 2285960 A1 CA2285960 A1 CA 2285960A1
Authority
CA
Canada
Prior art keywords
lactoferrin
inflammatory
tnf
lactofernn
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002285960A
Other languages
English (en)
French (fr)
Inventor
Ian Kimber
Marie Cumberbatch
Rebecca J. Dearman
Orla M. Conneely
Pauline Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2285960A1 publication Critical patent/CA2285960A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002285960A 1997-04-10 1998-04-10 Use of lactoferin in the treatment of allergen induced disorders Abandoned CA2285960A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4189097P 1997-04-10 1997-04-10
US60/041,890 1997-04-10
PCT/US1998/007234 WO1998044940A1 (en) 1997-04-10 1998-04-10 Use of lactoferin in the treatment of allergen induced disorders

Publications (1)

Publication Number Publication Date
CA2285960A1 true CA2285960A1 (en) 1998-10-15

Family

ID=21918897

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002285960A Abandoned CA2285960A1 (en) 1997-04-10 1998-04-10 Use of lactoferin in the treatment of allergen induced disorders

Country Status (12)

Country Link
US (1) US20030190303A1 (enExample)
EP (1) EP0979099B1 (enExample)
JP (1) JP2001519815A (enExample)
CN (1) CN1262625A (enExample)
AT (1) ATE297755T1 (enExample)
AU (1) AU747385C (enExample)
CA (1) CA2285960A1 (enExample)
DE (1) DE69830582T2 (enExample)
ES (1) ES2245028T3 (enExample)
IL (1) IL132293A0 (enExample)
NZ (1) NZ500712A (enExample)
WO (1) WO1998044940A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL336626A1 (en) * 1997-05-03 2000-07-03 Regents Board Of Methods of preventing and treating traumatic loss of metabolic equlibrium among human beings and animals
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001051079A1 (en) * 2000-01-14 2001-07-19 Meiji Dairies Corporation Antigen-specific ige antibody production inhibitors
RU2165769C1 (ru) * 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
EP1466621A4 (en) * 2001-12-28 2009-05-27 Nrl Pharma Inc COMPOSITIONS FOR ENHANCING LIPID METABOLISM
EP1477182A4 (en) 2002-01-21 2009-05-27 Nrl Pharma Inc NEW ANALGETICS
CA2484656A1 (en) * 2002-05-10 2003-12-04 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
US7238661B2 (en) * 2002-05-24 2007-07-03 Agennix, Inc. Oral lactoferrin in the treatment of respiratory disorders
SG2013096847A1 (en) 2002-09-06 2017-05-30 Medarex Llc Therapeutic human anti-il-1r1 monoclonal antibody
ES2358645T3 (es) * 2002-09-16 2011-05-12 Agennix Incorporated Composiciones de lactoferrina y métodos de tratamiento de la úlcera diabética.
JP4795021B2 (ja) * 2002-12-06 2011-10-19 エイジェニックス インコーポレイテッド 敗血症治療における経口用ラクトフェリン
AU2003296447A1 (en) 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
CA2527904A1 (en) 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
CA2566776C (en) * 2004-06-11 2011-08-02 Syngenta Limited Method for ameliorating an inflammatory skin condition
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
US8147875B2 (en) * 2005-03-15 2012-04-03 Campina Nederland Holding B.V. Dermatologic use of milk proteins
US8178486B2 (en) * 2005-07-21 2012-05-15 Animal Technology Institute Taiwan Method for promoting hair growth
JP2009514804A (ja) * 2005-10-14 2009-04-09 オークランド ユニサービシーズ リミティド ラクトフェリン断片及び加水分解物の使用
EP1952818A4 (en) * 2005-10-27 2009-10-21 Sunstar Inc OSTEOCLASTICIZATION PREPARATION, ORAL AGGREGATION AND PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST BONE DISEASES WITH LACTOFERRIN-CONTAINING LIPOSOME
WO2011130800A1 (en) * 2010-04-23 2011-10-27 Probiotec Limited Eczema treatment
CN102370964B (zh) * 2010-08-16 2015-12-09 李兴德 白细胞介素受体拮抗蛋白在制备皮肤外用制剂中的应用
IT201800002457A1 (it) * 2018-02-07 2019-08-07 Neilos S R L Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie
EP3836954B1 (en) 2018-08-13 2025-05-07 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2021116403A1 (en) * 2019-12-11 2021-06-17 N.V. Nutricia Nutritional composition for improving immune fitness
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596986B1 (fr) * 1986-04-11 1988-09-23 Sederma Sa Utilisation de la lactoferrine dans des preparations cosmetiques, antiradicaux libres
FR2641696B2 (fr) * 1986-04-11 1991-03-08 Sederma Sa Utilisation d'un melange renfermant de la lactoferrine dans des preparations cosmetiques anti-radicaux libres
FR2685202B1 (fr) * 1991-12-24 1995-03-24 Sederma Sa Nouvelle methode de traitement pharmaceutique et cosmetique pour la regulation de la seborrhee, de l'acne et de la flore cutanee.
JP3184923B2 (ja) * 1992-01-08 2001-07-09 ビオ セレ ラボラトワール エス ア 抗リウマチ剤
JPH05279266A (ja) * 1992-04-02 1993-10-26 Imuno Japan:Kk 歯周病の治療・予防用医薬組成物
JP3163171B2 (ja) * 1992-07-15 2001-05-08 森永乳業株式会社 ＩｇＡ産生促進剤
JP3746081B2 (ja) * 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
JPH0859450A (ja) * 1994-08-18 1996-03-05 Kose Corp 皮膚外用剤
JP2832517B2 (ja) * 1994-12-09 1998-12-09 雪印乳業株式会社 大腸菌付着阻止剤
JP3911642B2 (ja) * 1995-06-06 2007-05-09 株式会社加美乃素本舗 皮膚外用剤
JP3888707B2 (ja) * 1996-01-22 2007-03-07 森永乳業株式会社 血管新生病治療剤
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof

Also Published As

Publication number Publication date
ES2245028T3 (es) 2005-12-16
CN1262625A (zh) 2000-08-09
DE69830582T2 (de) 2006-05-04
NZ500712A (en) 2002-10-25
JP2001519815A (ja) 2001-10-23
AU6964798A (en) 1998-10-30
DE69830582D1 (de) 2005-07-21
WO1998044940A1 (en) 1998-10-15
EP0979099B1 (en) 2005-06-15
AU747385B2 (en) 2002-05-16
US20030190303A1 (en) 2003-10-09
IL132293A0 (en) 2001-03-19
ATE297755T1 (de) 2005-07-15
AU747385C (en) 2003-01-30
EP0979099A1 (en) 2000-02-16

Similar Documents

Publication Publication Date Title
AU747385C (en) Use of lactoferin in the treatment of allergen induced disorders
US10844101B2 (en) Plant-derived elastin binding protein ligands and methods of using the same
Angeletti et al. Healing rituals and sacred serpents
DE69228700T2 (de) Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände
JP3112844B2 (ja) サブスタンスｐアンタゴニストとしてランタニド、マンガン、またはイットリウムを含有する組成物
JPH07304649A (ja) 化粧品組成物においてサブスタンスｐアンタゴニストを使用する使用方法およびその組成物
US11298353B2 (en) Anti-inflammatory composition
AU2001275018B2 (en) Composition and method for enhancing elasticity of tissue
US20050054578A1 (en) Elastin peptide analogs and uses thereof
JP4689039B2 (ja) ファゴサイトーシスおよびｉｃａｍ−１発現を調節するための組成物および方法
US7666842B2 (en) Elastin peptide analogs and uses thereof
JP2008501772A (ja) 炎症性皮膚状態を寛解するための方法
Dati et al. Beneficial effects of rh-CLU on disease severity in different animal models of peripheral neuropathies
JP3520084B2 (ja) 多発性硬化症を含めた炎症の治療におけるペプチドｔ及びその関連ペプチド類
MXPA99009240A (en) Use of lactoferin in the treatment of allergen induced disorders
Zwadlo-Klarwasser et al. The effects of the glucocorticoids prednisolone, deflazacort and beclomethasone-dipropionate on the RM 3/1 macrophage in human peripheral blood
JP2023070539A (ja) オートファジー活性化剤
KR20220164450A (ko) Agkistrodon piscivorus piscivorus 또는 Naja melanoleuca로부터 유래된 신규한 펩타이드, 및 이를 포함하는 베체트병 또는 류마티스 관절염의 치료용 조성물
KR20240113008A (ko) p53을 활성화하는 펩타이드 및 이를 포함하는 조성물
WO2021187944A1 (ko) 코엔자임 q10 가용화 조성물의 치료학적 용도
JPWO1999064066A1 (ja) 硬ケラチンまたは硬ケラチン様物質を含有する免疫寛容誘導剤
Bae Stimulation of macrophage function by interphotoreceptor retinoid-binding protein: production of nitric oxide.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued